PureHealth, the largest healthcare platform in the Middle East, has invested Dh1 billion in local procurement to support the National ICV Programme since the first quarter of 2023. The programme is a key part of the UAE’s national industrial strategy, aiming to increase the industrial sector’s contribution to the GDP to Dh300 billion by 2031.
At the Make it in the Emirates Forum held at the Abu Dhabi Energy Centre, PureHealth revealed its progress towards the Dh13 billion target in local procurement by 2032. PureHealth continues to be a major national player and contributor to the UAE’s economic and social development, facilitating local healthcare manufacturing capabilities, creating employment opportunities, and delivering world-class health services.
Under an agreement with the Ministry of Industry and Advanced Technology (MoIAT) to join the National ICV Programme in 2022, PureHealth initially committed Dh10 billion to local procurement by 2032. In 2023, the commitment was increased by 30 percent to Dh13 billion. Additionally, PureHealth has extended its ICV strategies to its subsidiaries, such as Abu Dhabi Health Services Company (SEHA), Rafed, and Daman.
In August 2023, SEHA achieved the highest ICV score among UAE healthcare companies at 79.1 percent, with Daman also scoring 71.83 percent. Omar Al Suwaidi, Undersecretary of MoIAT, stated that the Ministry aims to promote the ICV Programme as part of the 'Projects of the 50' of the UAE, emphasizing its role in enhancing and empowering the industrial and advanced technology sectors.
Shaista Asif, Group CEO of PureHealth, expressed pride in PureHealth's participation in the Make it in the Emirates Forum, highlighting the strong progress made towards the target of spending Dh13 billion with local suppliers over the next decade. This commitment signifies an expanded support for UAE-based manufacturers and underscores PureHealth's essential role in national health security, industrial growth, and economic progress.
